Pacira Pharmaceuticals (NASDAQ: PCRX) and Concordia International Corp. (NASDAQ:CXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.


This table compares Pacira Pharmaceuticals and Concordia International Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacira Pharmaceuticals -23.36% -12.44% -6.07%
Concordia International Corp. -269.97% -83.96% -0.62%

Analyst Recommendations

This is a summary of current ratings for Pacira Pharmaceuticals and Concordia International Corp., as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira Pharmaceuticals 0 8 9 0 2.53
Concordia International Corp. 5 1 0 0 1.17

Pacira Pharmaceuticals presently has a consensus target price of $53.42, indicating a potential upside of 48.79%. Concordia International Corp. has a consensus target price of $8.00, indicating a potential upside of 545.16%. Given Concordia International Corp.’s higher possible upside, analysts plainly believe Concordia International Corp. is more favorable than Pacira Pharmaceuticals.

Valuation and Earnings

This table compares Pacira Pharmaceuticals and Concordia International Corp.’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Pacira Pharmaceuticals $281.47 million 5.15 -$34.94 million ($1.71) -20.99
Concordia International Corp. $677.25 million 0.09 $326.58 million ($35.65) -0.03

Concordia International Corp. has higher revenue and earnings than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than Concordia International Corp., indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.1% of Concordia International Corp. shares are owned by institutional investors. 6.6% of Pacira Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Pacira Pharmaceuticals has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Concordia International Corp. has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.


Pacira Pharmaceuticals beats Concordia International Corp. on 8 of the 13 factors compared between the two stocks.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Concordia International Corp. Company Profile

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.